| Name | Title | Contact Details |
|---|---|---|
Charles Marra |
Vice President of Technology | Profile |
Nick Gianadda |
Chief Technology Officer | Profile |
Twentyeight-Seven Therapeutics is a focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases.
Hess Associates is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.
Antibody Solutions is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blue Sky Biotech Inc is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.